DM Pharma, SCO 165, Sector 38-C, Chandigarh

Company Name : DM Pharma

Address : SCO 165, Sector 38-C, Chandigarh

Tel No: 09356053628, 09463087467

Email : saarbiotechda@gmail.com

Website : http://www.dmpharmachd.com/

Company Profile

DM Pharma is an emerging, global pharmaceutical company with proven capabilities in the areas of product research, manufacturing & marketing.

Over the years, DM Pharma has emerged as one of the fastest growing Indian pharmaceutical companies. Our focus on specialty segments in India and simultaneous opening of newer markets abroad has helped us maintain the growth. We are firmly establishing our brands in each market for sustained sales. DM has established strong capabilities in the international market with exports contributing a substantial part of the total revenues.

DM was incorporated in 1999 and has since moved up the value chain from being a small manufacturer to a vibrant marketing and research-oriented company. DM is now one of the leading pharmaceutical companies from India.

Our manufacturing capability includes a wide range of therapeutic products covering segments like Anti-retrovirals, Anti-malarials, Cardiovascular, Dermatology and Ophthalmology among others. We also market OTC products in many international markets that include some nature-based remedies.

Given our strong emphasis on product quality and service, DM Pharma has been approved to supply medicines to various Government Institutions like Health Departments, Defence services and hospitals in India. DM is also certified supplier to many big institutions and voluntary organizations like MSF and PSF, within and outside the country.

DM is committed to develop new technologies. We have been able to launch products with enhanced release profiles to ensure better treatment compliance and dosage convenience.

The pharmaceutical packaging market in India is growing by approximately 10 to 15 percent per year, particularly in the higher quality segments, according to industry analysis. India has the largest number of U.S. Food and Drug Administration approved plants outside of the United States, for example. The joint venture will support Indian pharmaceutical companies in upgrading products for international markets by supplying pharmaceutical packaging at an international quality level from the Indian production site.